Allergy and Immunology
Schwartz Lab

Schwartz Research Lab

The Schwartz Lab conducts translational research focused on the roles of innate immune cells in the development, progression, and resolution of allergic disease in children.

Eosinophils represent an important effector cell within the innate immune system and play a central role in atopy and dysregulated immune responses. How these cells are regulated and modulate innate and adaptive immune responses remains understudied and a unique scientific niche. We investigate human eosinophil development and their effector roles in eosinophilic inflammation and contribute to the research and treatment of eosinophilic disorders, such as eosinophilic gastrointestinal disorders (EGIDs), through the Cincinnati Center for Eosinophilic Disorders. Our current research focuses on how eosinophils and their precursor cells, eosinophil progenitors (EoPs), contribute to the eosinophilic inflammation of EGIDs, such as eosinophilic esophagitis (EoE).

The Schwartz Lab has a developing research program in food allergy and peanut oral immunotherapy (OIT). Oral immunotherapy is an emerging treatment for children with food allergy. Few immunologic biomarkers can predict which patients will respond better to this therapy or monitor responses associated with long-term benefits. Our lab is characterizing early immunologic responses to oral immunotherapy to determine whether these responses could be leveraged as biomarkers for predicting responses to therapy. This research employs the resources of the Food Allergy Program as a pipeline for research sample collection from our expanding OIT patient cohort.

Eosinophil Progenitors in EoE

As published in the Journal of Allergy and Clinical Immunology, blood eosinophil progenitors (EoPs) correlate with tissue pathology during active eosinophilic esophagitis (EoE), providing additional evidence for blood EoP levels as a biomarker for disease activity and suggesting a role for EoPs in EoE pathogenesis. Read the publication now.

About the PI

A photo of Justin Schwartz.

Justin T. Schwartz, MD, PhD

My special interests are in food allergy, oral immunotherapy and eosinophilic disorders.

I have a strong commitment to addressing pediatric immune disorders through a coordinated approach to clinical care and translational research.


Kliewer, KL; Murray-Petzold, C; Collins, MH; Abonia, JP; Bolton, SM; DiTommaso, LA; Martin, LJ; Zhang, X; Mukkada, VA; Putnam, PE; et al. Benralizumab for eosinophilic gastritis: a single-site, randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Gastroenterology and Hepatology. 2023; 8:803-815.

Guarnieri, KM; Saba, NK; Schwartz, JT; Devonshire, AL; Bufford, J; Casale, TB; Rothenberg, ME; Andorf, S. Food Allergy Characteristics Associated With Coexisting Eosinophilic Esophagitis in FARE Registry Participants. Journal of Allergy and Clinical Immunology: In Practice. 2023; 11:1509-1521.e6.

Gill, K; Moore, C; Nwogu, O; Kroner, JW; Chang, W; Stevens, ML; Baatyrbek Kyzy, A; Biagini, JM; Devonshire, AL; Kottyan, L; et al. B cell repertoire in children with skin barrier dysfunction supports altered IgE maturation associated with allergic food sensitization. 2023; 4:2023.02.01.526538.

Underwood, B; Troutman, TD; Schwartz, JT. Breaking down the complex pathophysiology of eosinophilic esophagitis. Annals of Allergy, Asthma, and Immunology. 2023; 130:28-39.

Dill-McFarland, KA; Schwartz, JT; Zhao, H; Shao, B; Fulkerson, PC; Altman, MC; Gill, MA. Eosinophil-mediated suppression and anti-IL-5 enhancement of plasmacytoid dendritic cell interferon responses in asthma. Journal of Allergy and Clinical Immunology. 2022; 150:666-675.

Wright, BL; Schwartz, JT; Ruffner, MA; Furuta, GT; Gonsalves, N; Dellon, ES; Aceves, SS. Eosinophilic gastrointestinal diseases make a name for themselves: A new consensus statement with updated nomenclature. Journal of Allergy and Clinical Immunology. 2022; 150:291-293.

Droghini, HR; Abonia, JP; Collins, MH; Milner, JD; Lyons, JJ; Freeman, AF; Mukkada, VA; Risma, KA; Rothenberg, ME; Schwartz, JT. Targeted IL-4Rα blockade ameliorates refractory allergic eosinophilic inflammation in a patient with dysregulated TGF-β signaling due to ERBIN deficiency. Journal of Allergy and Clinical Immunology: In Practice. 2022; 10:1903-1906.

Felton, JM; Bouffi, C; Schwartz, JT; Schollaert, KL; Malik, A; Vallabh, S; Wronowski, B; Magier, AZ; Merlin, L; Barski, A; et al. Aiolos regulates eosinophil migration into tissues. Mucosal Immunology. 2021; 14:1271-1281.

Slack, IF; Schwartz, JT; Mukkada, VA; Hottinger, S; Abonia, JP. Eosinophilic Esophagitis: Existing and Upcoming Therapies in an Age of Emerging Molecular and Personalized Medicine. Current Allergy and Asthma Reports. 2020; 20:30.

Lindsley, AW; Schwartz, JT; Rothenberg, ME. Eosinophil responses during COVID-19 infections and coronavirus vaccination. Journal of Allergy and Clinical Immunology. 2020; 146:1-7.

Henderson, A; Magier, A; Schwartz, JT; Martin, LJ; Collins, MH; Putnam, PE; Mukkada, VA; Abonia, JP; Rothenberg, ME; Fulkerson, PC. Monitoring Eosinophilic Esophagitis Disease Activity With Blood Eosinophil Progenitor Levels. Journal of Pediatric Gastroenterology and Nutrition. 2020; 70:482-488.

Schwartz, JT; Morris, DW; Collins, MH; Rothenberg, ME; Fulkerson, PC. Eosinophil progenitor levels correlate with tissue pathology in pediatric eosinophilic esophagitis. Journal of Allergy and Clinical Immunology. 2019; 143:1221-1224.e3.

Schwartz, JT; Magier, AZ; Marshall, SA; Fulkerson, PC. Eosinophil progenitor cell blood levels inversely correlate with disease control in pediatric patients with asthma. Journal of Allergy and Clinical Immunology. 2019; 143:ab5.